Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1545288 | 0.97 | KMT2A (0.64) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL7228185 | 0.92 | KMT2A (0.62) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL8125031 | 0.92 | KMT2A (0.59) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL6856717 | 0.91 | KMT2A (0.76) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL27906226 | 0.88 | TSHR (0.68) | PRSS1TSHRMAPTHTT | |
| SCHEMBL1545264 | 0.87 | MAPK1 (0.68) | KMT2APRSS1TSHRMAPK1CYP1A2 | |
| SCHEMBL4376688 | 0.87 | MAPT (0.59) | KMT2APRSS1TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL10260429 | 0.86 | KMT2A (0.66) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL470710 | 0.86 | KMT2A (0.66) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL29842346 | 0.86 | KMT2A (0.66) | KMT2AMAOBMEN1PRSS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110087729-B | Bifunctional compound with quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3556435-B1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3556435-A1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | Beijing Showby Pharmaceutical Co., Ltd. (CN) | 2019-10-23 | — | — | EP | disclosed |
| CN-110087729-A | One kind has the dual-function compound of quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2019-08-02 | — | — | CN | disclosed |
| WO-2011154860-A1 | AN IMPROVED PROCESS FOR PREPARING ILOPERIDONE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2011-12-15 | — | — | WO | disclosed |
| EP-0892802-B1 | SPIRO(CYCLOPENT(B)INDOLE-PIPERIDINES) AND N-PHENYL-HYDRAZON INTERMEDIATES FOR THEIR PREPARATION, BOTH BEING ACETYLCHOLINESTERASE AND MAO INHIBITORS | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-6479501-B2 | COGNITION ACTIVATORS; ANTIDEPRESSANTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020004601-A1 | Spiro[cyclopent[b]indole-piperidines] | HOECHST MARION ROUSSEL, INC. | 2002-01-10 | — | — | US | disclosed |
| US-6229014-B1 | 8-AZASPIRO(4.5)DECANE-1-ONE; ANTIDEPRESSANTS AND TREATMENT OF PSYCHOLIGICAL DISORDERS, SPECIFICALLY MEMORY LOSS | HOECHST MARION ROUSSEL, INC. (FR) | 2001-05-08 | — | — | US | disclosed |
| US-6156901-A | Spiro[cyclopent[b]indole-piperidines] | HOECHST MARION ROUSSEL, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0587048-B1 | Heteroarenylpiperazines, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1997037992-A2 | SPIRO[CYCLOPENT[B]INDOLE-PIPERIDINES] AND N-PHENYL-HYDRAZON INTERMEDIATES FOR THEIR PREPARATION, BOTH BEING ACETYLCHOLINESTERASE AND MAO INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
| EP-0570850-B1 | Benzo(b)thiophen-3-yl-piperazines, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0587048-A2 | Heteroarenylpiperazines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5272148-A | Heteroarenylpiperazines | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0570850-A1 | Benzo(b)thiophen-3-yl-piperazines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-11-24 | — | — | EP | disclosed |
| US-5240927-A | Benzo[β]thiophen-3-yl piperazines as antipsychotic agents | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-08-31 | — | — | US | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| US-4810713-A | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0235463-A2 | N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004601-A1 | Spiro[cyclopent[b]indole-piperidines] | CAMK2B, GRIN2B, HTR2B | KMT2A 3480/4885MAOB 103/4885MEN1 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.